SCHEMBL27218688

SCHEMBL27218688

Cc1cc(N)nc(SCc2nc(-c3cccnc3)no2)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.62
▸ LMNA P02545 3/20 0.62
▸ MAPK1 P28482 3/20 0.62
▸ RAB9A P51151 5/20 0.61
▸ NPC1 O15118 4/20 0.61
▸ SMN1; SMN2 Q16637 4/20 0.61
▸ HTT P42858 1/20 0.61
▸ L3MBTL1 Q9Y468 2/20 0.51
▸ PPARA Q07869 1/20 0.49
▸ MAPT P10636 2/20 0.48
▸ POLB P06746 1/20 0.48
▸ KMT2A Q03164 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ TSHR P16473 4/20 0.47
▸ ATM Q13315 1/20 0.47
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31494430 0.88 SMN1; SMN2 (0.72) ALDH1A1LMNAMAPK1RAB9ANPC1
SCHEMBL27218886 0.86 SMN1; SMN2 (0.70) ALDH1A1LMNAMAPK1RAB9ANPC1
SCHEMBL31494448 0.80 RAB9A (0.64) ALDH1A1LMNAMAPK1RAB9ANPC1
SCHEMBL27218936 0.80 RAB9A (0.71) ALDH1A1LMNAMAPK1RAB9ANPC1
SCHEMBL27218874 0.79 HTT (0.69) ALDH1A1LMNAMAPK1RAB9ANPC1
SCHEMBL27218810 0.79 NPC1 (0.61) ALDH1A1LMNARAB9ANPC1SMN1; SMN2
SCHEMBL27218899 0.78 SMN1; SMN2 (0.58) ALDH1A1LMNAMAPK1RAB9ANPC1
SCHEMBL27218761 0.77 RAB9A (0.64) ALDH1A1LMNAMAPK1RAB9ANPC1
SCHEMBL27218828 0.76 RAB9A (0.53) ALDH1A1LMNAMAPK1RAB9ANPC1
SCHEMBL31494416 0.75 RAB9A (0.54) ALDH1A1LMNAMAPK1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 ALDH1A1 1767/4885LMNA 3526/4885MAPK1 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback